RecruitingPhase 3NCT06624670
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
Studying Classic pyoderma gangrenosum
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Boehringer Ingelheim
- Intervention
- Spesolimab(drug)
- Enrollment
- 90 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2028
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Medical Dermatology Specialists Phoenix, Phoenix, Arizona, United States
- University of California Irvine, Irvine, California, United States
- University of Miami, Miami, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Dawes Fretzin Clinical Research Group, LLC-Indianapolis -68995, Indianapolis, Indiana, United States
- Tulane University Hospital and Clinic, New Orleans, Louisiana, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Dartmouth Hitchcock Clinics Heater Road, Lebanon, New Hampshire, United States
- Dermatology at Lake Success, Lake Success, New York, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Red River Research Partners, LLC, Fargo, North Dakota, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06624670 on ClinicalTrials.govOther trials for Classic pyoderma gangrenosum
Additional recruiting or active studies for the same condition.